07 Dec GenXys Named to the 2022 CB Insights Digital Health 150 List
GenXys recognized for achievements in precision prescribing platform
NEW YORK, December 7, 2022 — CB Insights today named GenXys to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022.
“From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”
“We are honored and proud to be named to the Digital Health 150 List and add it to our recent accolades, but really it’s a nod to how our platform is used to improve patient safety and increase population health,” says Karl Pringle, CEO of GenXys. “Remembering that Adverse Drug Reactions are a top five cause of death in every major country, our customers and global partners speak volumes about how our proven precision prescribing software is digitally transforming the centuries old approach to prescribing. Our auto inclusion of pharmacogenetics into the prescribing process has really catapulted us into a category-defining position.”
Utilizing the CB Insights platform, the research team selected these 150 winners from a pool of over 13,000 private companies, including applicants and nominees. They were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed over 3,000 Analyst Briefings submitted by applicants.
GenXys provides the world’s most comprehensive precision prescribing solutions that enable any clinician at any point of care to seamlessly make accurate prescribing choices or complete medication reviews with embedded pharmacogenetics to solve one of healthcare’s biggest challenges: inappropriate (“trial-and-error”) prescribing.
Quick facts on the 2022 Digital Health 150:
- Equity funding and deals: Since 2017, this year’s Digital Health 150 winners have raised around $5.6B in equity funding across 378 deals. This includes approximately $1.6B raised across 85 deals in 2022 YTD alone.
- Unicorns: This year’s list includes only 5 unicorns with a $1B+ valuation, around 3% of the total list. For comparison, last year’s list contained 17. This tracks with a broader drop in new unicorns across sectors in 2022.
- Global Reach: Winners in this year’s Digital Health 150 span 18 countries across 5 continents. A quarter (25%) are headquartered outside of the US — the most in the history of our list. While the US still leads, the UK comes in second with 9 winners, followed by Canada with 5 and Brazil with 3.
About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
Contact:
About GenXys Health Care Systems
GenXys, with a presence across North America, provides the world’s most comprehensive precision prescribing solutions with embedded pharmacogenetics to solve one of healthcare’s biggest challenges: inappropriate (“trial-and-error”) prescribing. GenXys’ clinical decision support software suite is in use by major insurance providers, health systems, pharmacies, and their pharmacogenetic labs across North America. We work globally with leading genetic infrastructure companies to help enable our vision of making every prescription better with its software to increase patient safety, improve population health, and reduce healthcare costs. https://www.genxys.com/
Contact:
Sorry, the comment form is closed at this time.